Oosterkamp Stephanie, de Jong Jos M A, Van den Ende Piet L, Manni Johannes J, Dehing-Oberije Cary, Kremer Bernd
Department of Otorhinolaryngology and Head & Neck Surgery, Maastricht, The Netherlands.
Laryngoscope. 2006 Nov;116(11):2067-70. doi: 10.1097/01.mlg.0000240263.05198.a0.
The objective of this retrospective chart analysis was to determine the prognostic value of the lymph node status and extracapsular lymph node extension (ECE) of the neck for the development of distant metastases in squamous cell carcinoma of the larynx.
One hundred sixty-five patients treated for laryngeal carcinoma with a neck dissection with histologic evaluation were included. Primary study end point was distant metastasis-free survival. Univariate analysis with the Kaplan-Meier method was used to calculate distant metastasis-free survival and overall survival for the whole group and for groups according to ECE/lymph node status. Patients were classified as 1) no metastatic lymph nodes, 2) metastatic lymph nodes without ECE, or 3) metastatic lymph nodes with ECE. Univariate Cox regression was performed with outcome distant metastasis-free survival.
The median overall survival for the whole group was 5.1 years and the 5-year survival rate was 51%. The median distant metastasis-free survival for the whole group could not be calculated and the 5-year metastasis-free survival rate was 78%. The hazard ratio was 3.4 (95% confidence interval [CI] = 1.0-12.1) for patients with positive nodes and without ECE and 10.5 (95% CI = 3.6-30.8) for the patients with metastatic nodes and with ECE compared with the patients without metastatic lymph nodes.
The presence of ECE in metastatic lymph nodes augments the risk of distant metastasis by nine times in laryngeal carcinoma. Metastatic lymph nodes without ECE show a risk three times greater.
本回顾性病历分析的目的是确定喉鳞状细胞癌颈部淋巴结状态及淋巴结包膜外扩展(ECE)对远处转移发生的预后价值。
纳入165例接受喉癌颈清扫术并进行组织学评估的患者。主要研究终点为无远处转移生存期。采用Kaplan-Meier法进行单因素分析,以计算整个组以及根据ECE/淋巴结状态分组后的无远处转移生存期和总生存期。患者分为1)无转移性淋巴结;2)有转移性淋巴结但无ECE;或3)有转移性淋巴结且有ECE。对无远处转移生存期这一结局进行单因素Cox回归分析。
整个组的中位总生存期为5.1年,5年生存率为51%。整个组的中位无远处转移生存期无法计算,5年无转移生存率为78%。有阳性淋巴结但无ECE的患者的风险比为3.4(95%置信区间[CI]=1.0-12.1),有转移性淋巴结且有ECE的患者与无转移性淋巴结的患者相比,风险比为10.5(95%CI=3.6-30.8)。
转移性淋巴结中存在ECE会使喉癌远处转移风险增加9倍。无ECE的转移性淋巴结显示风险增加3倍。